Health Law Update

Home | Health Law Update

<img class="alignright size-medium wp-image-3098" src="https://healthlawupdate.bakerhostetlerblogs.com/wp-content/uploads/sites/19/2015/05/pharma-iStock_000061614090_Large-300x200.jpg" alt="pharma iStock_000061614090_Large" width="300" height="200">FDA had a busy holiday season, issuing two final guidance documents and two draft guidance documents for industry related to human drug compounding right before the start of the new year. These guidance documents cover prescription requirements under Section 503A of the Federal Food, Drug, and Cosmetic Act (FFDCA); compounding and repackaging of radiopharmaceuticals; and electronic drug product reporting by Outsourcing Facilities under the FFDCA. <strong><a href="https://www.bakerlaw.com/alerts/human-drug-compounding-fda-issues-four-guidance-documents">Read more &gt;&gt;</a></strong>

Human Drug Compounding: FDA Issues Four Guidance Documents